Recombinant Human Interferon-β (rHuIFN-β) and Radiation Therapy for Inoperable Non-Small Cell Lung Cancer

Roger W. Byhardt(Milwaukee VA Medical Center), ERNEST C. BORDEN(Medical College of Wisconsin), Louis Vaickus(Boston University), James B. Breitmeyer(Therapeutics Clinical Research), Patricia L. Witt(Medical College of Wisconsin), MARY ELLEN ALGER(Merck KGaA, Darmstadt (Germany)), C.A. Lawton(Medical College of Wisconsin), Alex Y. Chang(Cornell University), J. Frank Wilson(Medical College of Wisconsin), Timothy L. McAuliffe(Medical College of Wisconsin)
Journal of Interferon & Cytokine Research
November 1, 1996
10.1089/jir.1996.16.891
Cited by 16

Related Papers

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
|The Lancet|2005|2.1k
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2006|705
Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer
|CHEST Journal|2000|632
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
|Journal of Clinical Oncology|2018|473
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
|Lung Cancer|2010|441